Advances in Huntington’s Disease Biomarkers: A 10-Year Bibliometric Analysis and a Comprehensive Review
Biology,
Год журнала:
2025,
Номер
14(2), С. 129 - 129
Опубликована: Янв. 26, 2025
Neurodegenerative
disorders
(NDs)
cause
progressive
neuronal
loss
and
are
a
significant
public
health
concern,
with
NDs
projected
to
become
the
second
leading
global
of
death
within
two
decades.
Huntington’s
disease
(HD)
is
rare,
ND
caused
by
an
autosomal-dominant
mutation
in
huntingtin
(HTT)
gene,
severe
brain
resulting
debilitating
motor,
cognitive,
psychiatric
symptoms.
Given
complex
pathology
HD,
biomarkers
essential
for
performing
early
diagnosis,
monitoring
progression,
evaluating
treatment
efficacy.
However,
identification
consistent
HD
challenging
due
prolonged
premanifest
stage,
HD’s
heterogeneous
presentation,
its
multiple
underlying
biological
pathways.
This
study
involves
10-year
bibliometric
analysis
biomarker
research,
revealing
key
research
trends
gaps.
The
also
features
comprehensive
literature
review
emerging
biomarkers,
concluding
need
better
stratification
patients
well-designed
longitudinal
studies
validate
biomarkers.
Promising
candidate
wet
biomarkers—
including
neurofilament
light
chain
protein
(NfL),
microRNAs,
mutant
HTT
protein,
specific
metabolic
inflammatory
markers—
discussed,
emphasis
on
their
potential
utility
stage.
Additionally,
reflecting
structural
deficits
motor
or
behavioral
impairments,
such
as
neurophysiological
(e.g.,
tapping,
speech,
EEG,
event-related
potentials)
imaging
MRI,
PET,
diffusion
tensor
imaging)
evaluated.
findings
underscore
that
discovery
validation
reliable
urgently
require
improved
patient
studies.
Reliable
particularly
crucial
optimizing
clinical
management
strategies,
enabling
personalized
approaches,
advancing
trials
HD-modifying
therapies.
Язык: Английский
Cerebellar Pathology in Forensic and Clinical Neuroscience
Ageing Research Reviews,
Год журнала:
2025,
Номер
unknown, С. 102697 - 102697
Опубликована: Фев. 1, 2025
Язык: Английский
The value of serum glial fibrillary acidic protein as a biomarker of astrogliosis in different neurological diseases
Clinica Chimica Acta,
Год журнала:
2025,
Номер
unknown, С. 120248 - 120248
Опубликована: Март 1, 2025
Язык: Английский
The Janus Face of Oxidative Stress and Hydrogen Sulfide: Insights into Neurodegenerative Disease Pathogenesis
Antioxidants,
Год журнала:
2025,
Номер
14(3), С. 360 - 360
Опубликована: Март 19, 2025
Oxidative
stress
plays
an
essential
role
in
neurodegenerative
pathophysiology,
acting
as
both
a
critical
signaling
mediator
and
driver
of
neuronal
damage.
Hydrogen
sulfide
(H2S),
versatile
gasotransmitter,
exhibits
similarly
“Janus-faced”
nature,
potent
antioxidant
cytoprotective
molecule
at
physiological
concentrations,
but
becoming
detrimental
when
dysregulated.
This
review
explores
the
dual
roles
oxidative
H2S
normal
cellular
physiology
focusing
on
disease
progression.
We
highlight
potential
therapeutic
opportunities
for
targeting
redox
sulfur-based
systems
diseases
by
elucidating
intricate
balance
between
these
opposing
forces.
Язык: Английский
Advances in Understanding Biomarkers and Treating Neurological Diseases -Role of the Cerebellar Dysfunction and Emerging Therapies
Ageing Research Reviews,
Год журнала:
2024,
Номер
unknown, С. 102519 - 102519
Опубликована: Сен. 1, 2024
Язык: Английский
The role of inflammation in neurological disorders: a brief overview of multiple sclerosis, Alzheimer’s, and Parkinson’s disease’
Frontiers in Neurology,
Год журнала:
2024,
Номер
15
Опубликована: Окт. 29, 2024
Neuroinflammation
is
a
central
feature
in
the
pathophysiology
of
several
neurodegenerative
diseases,
including
MS,
AD,
and
PD.
This
review
aims
to
synthesize
current
research
on
role
inflammation
these
conditions,
emphasizing
potential
inflammatory
biomarkers
for
diagnosis
treatment.
We
highlight
recent
findings
mechanisms
neuroinflammation,
utility
disease
differentiation,
implications
therapeutic
strategies.
Advances
understanding
pathways
offer
promising
avenues
developing
targeted
interventions
improve
patient
outcomes.
Future
should
focus
validating
larger
cohorts
integrating
them
into
clinical
practice
enhance
diagnostic
accuracy
efficacy.
Язык: Английский
Advances and Challenges in Gene Therapy for Neurodegenerative Diseases: A Systematic Review
International Journal of Molecular Sciences,
Год журнала:
2024,
Номер
25(23), С. 12485 - 12485
Опубликована: Ноя. 21, 2024
This
review
explores
recent
advancements
in
gene
therapy
as
a
potential
treatment
for
neurodegenerative
diseases,
focusing
on
intervention
mechanisms,
administration
routes,
and
associated
limitations.
Following
the
PRISMA
procedure
guidelines,
we
systematically
analyzed
studies
published
since
2020
using
PICO
framework
to
derive
reliable
conclusions.
The
efficacy
of
various
therapies
was
evaluated
Parkinson's
disease
(n
=
12),
spinal
muscular
atrophy
8),
Huntington's
3),
Alzheimer's
amyotrophic
lateral
sclerosis
6).
For
each
condition,
assessed
therapeutic
approach,
curative
or
disease-modifying
potential,
delivery
methods,
advantages,
drawbacks,
side
effects.
Results
indicate
that
targeting
specific
genes
are
particularly
effective
monogenic
disorders,
with
promising
clinical
outcomes
expected
near
future.
In
contrast,
polygenic
primarily
aim
promote
cell
survival.
A
major
challenge
remains:
translation
animal
model
success
human
application.
Additionally,
while
intracerebral
methods
enhance
efficacy,
they
highly
invasive.
Despite
these
hurdles,
represents
frontier
underscoring
need
continued
research
refine
personalize
treatments
condition.
Язык: Английский
Cerebrospinal Fluid Classical Biomarker Levels in Mixed vs. Pure A+T+ (A+T1+) Alzheimer’s Disease
Biomedicines,
Год журнала:
2024,
Номер
12(12), С. 2904 - 2904
Опубликована: Дек. 20, 2024
Background:
Alzheimer’s
disease
(AD)
may
present
with
pure
(typical
or
atypical)
and
mixed
phenotypes,
sometimes
causing
difficulties
in
(differential)
diagnosis.
In
order
to
achieve
a
diagnostic
accuracy
as
high
possible,
the
diagnosis
of
AD
during
life
depends
on
various
biomarkers,
including
cerebrospinal
fluid
(CSF)
biomarkers.
Methods:
Classical
CSF
biomarkers
were
determined
total
61
patients,
classified
both
beta
amyloid-
tau-positive
A+T+
(or
A+T1+
according
recently
revised
Alzheimer
Association
criteria
for
staging
AD).
Twenty
one
these
patients
fulfilled
(mixed
Lewy
bodies,
cerebrovascular
disease,
normal
pressure
hydrocephalus),
whilst
40
had
AD.
Results:
Patients
did
not
differ
respect
gender,
education,
duration,
cognitive
status.
After
controlling
confounding
factors,
no
difference
was
observed
between
groups
Aβ42
Aβ42/Aβ40
levels.
Although
by
definition,
abnormal
(increased)
levels
phospho-tau181,
group
presented
lower
(less
abnormal)
phospho-tau181
tau
compared
group.
Conclusions:
comparable
status,
cases
proteins
and,
if
close
cut-off
values,
uncertainty
be
increased.
Язык: Английский
Fluid-based biomarkers in neurodegeneration: Current findings and future directions
Medicinski podmladak,
Год журнала:
2024,
Номер
75(5), С. 23 - 30
Опубликована: Янв. 1, 2024
With
the
increase
in
life
expectancy,
prevalence
of
neurodegenerative
disorders
is
expected
to
rise
many
countries
world.
The
need
for
reliable
biomarkers
diseases
crucial
improving
timely
and
accurate
clinical
diagnostics,
facilitating
development
disease-modifying
therapies,
monitoring
patient
progress.
In
cases,
complex
pathology
can
be
reflected
extracellular
fluid,
allowing
soluble
that
mirror
neuropathology
cerebrospinal
fluid
or
blood.
This
review
an
overview
current
findings,
latest
developments
field,
as
well
applications
fluid-based
diseases.
Язык: Английский